Recce Pharmaceuticals (ASX:RCE) has entered into a Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research Institute of Infectious Diseases (USAMRIID), with partnership and funding from the Defense Threat Reduction Agency.
USAMRIID will test the company's synthetic anti-infective RECCE 327 (R327) against a panel of biodefence pathogens in its established in vitro infection models.
The following evaluation phase may progress to small animal model testing upon successful testing. USAMRIID is the US Army’s premier institution and facility for defensive research into countermeasures against biological warfare. The Institute is the only laboratory in the US Department of Defense (DOD) equipped to safely study highly hazardous pathogens requiring maximum containment at Biosafety Level 4.
USAMRIID’s biodefense testing partnership is in addition to and runs parallel to a recently awarded US$2 million burn wound grant by the US Department of Defense Congressionally Directed Medical Research Program (CDMRP) seeking to accelerate the development of R327G and evaluate it as a gel-based treatment to rapidly resolve burn wound infections.
Recce CEO James Graham said, “We are thrilled to enter into another US Department of Defense Research program, this time with the United States Army Medical Research Institute of Infectious Diseases and are very thankful for our partners at USAMRIID and DTRA. This program will see the U.S. Army test R327 against some of the world’s deadliest pathogens and comes in addition to an ongoing DoD burn wound program, further bolstering Recce’s ongoing US Government partnerships.”
